These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 24524212)

  • 1. Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study.
    Wu S; Chee D; Ugalde A; Butow P; Seymour J; Schofield P
    Palliat Support Care; 2015 Apr; 13(2):255-63. PubMed ID: 24524212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
    Eliasson L; Clifford S; Barber N; Marin D
    Leuk Res; 2011 May; 35(5):626-30. PubMed ID: 21095002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.
    Chen LC; Chen TC; Huang YB; Chang CS
    Int J Clin Pharm; 2014 Feb; 36(1):120-7. PubMed ID: 24154825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
    Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
    Lam MS; Cheung N
    J Oncol Pharm Pract; 2016 Dec; 22(6):741-748. PubMed ID: 26419691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
    Singh S; Sharma PK
    Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
    Daouphars M; Ouvry M; Lenain P; Rouvet J; Jardin F; Bubenheim M; Varin R
    Pharmacotherapy; 2013 Feb; 33(2):152-6. PubMed ID: 23359430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to imatinib among patients attending Saskatchewan Cancer Agency Pharmacies.
    Dicus M; Lyons B; Olson C; Tran DA; Blackburn DF
    J Oncol Pharm Pract; 2015 Dec; 21(6):403-8. PubMed ID: 24903271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study).
    Obeng-Kusi M; MacDonald K; van Lierde MA; Lee CS; De Geest S; Abraham I
    Leuk Res; 2021 Dec; 111():106734. PubMed ID: 34735932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.
    Efficace F; Rosti G; Cottone F; Breccia M; Castagnetti F; Iurlo A; Mandelli F; Baccarani M
    Leuk Res; 2014 Mar; 38(3):294-8. PubMed ID: 23906625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus.
    Daleboudt GM; Broadbent E; McQueen F; Kaptein AA
    Arthritis Care Res (Hoboken); 2011 Mar; 63(3):342-50. PubMed ID: 21120967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication adherence perspectives in haemodialysis patients: a qualitative study.
    Ghimire S; Castelino RL; Jose MD; Zaidi STR
    BMC Nephrol; 2017 May; 18(1):167. PubMed ID: 28532480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian's with chronic myeloid leukemia.
    Mulu Fentie A; Tadesse F; Engidawork E; Gebremedhin A
    PLoS One; 2019; 14(3):e0213557. PubMed ID: 30845227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate induced erythroderma: A rare case series.
    Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
    J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to multiple, prescribed medications in diabetic kidney disease: A qualitative study of consumers' and health professionals' perspectives.
    Williams AF; Manias E; Walker R
    Int J Nurs Stud; 2008 Dec; 45(12):1742-56. PubMed ID: 18701103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.
    Cerny-Reiterer S; Rabenhorst A; Stefanzl G; Herndlhofer S; Hoermann G; Müllauer L; Baumgartner S; Beham-Schmid C; Sperr WR; Mannhalter C; Sill H; Linkesch W; Arock M; Hartmann K; Valent P
    Oncotarget; 2015 Feb; 6(5):3071-84. PubMed ID: 25605011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
    Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy.
    Li Y; Wang CL; Din B; Yu L; Zhu J
    Acta Haematol; 2017; 137(3):158-162. PubMed ID: 28399540
    [No Abstract]   [Full Text] [Related]  

  • 20. Intentional Nonadherence as a Means to Exert Control.
    Huyard C; Derijks L; Haak H; Lieverse L
    Qual Health Res; 2017 Jul; 27(8):1215-1224. PubMed ID: 28682739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.